Ligand Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
LGND Ligand Pharmaceuticals Inc
EFC Ellington Financial Inc
CBRG Chain Bridge I
DSX Diana Shipping Inc
VNO Vornado Realty Trust
PSA Public Storage
BSL Blackstone Senior Floating Rate Term
CPSI Computer Programs and Systems Inc
PARA Paramount Global
TLGA TLG Acquisition One Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.

Closing Price
$87.03
Day's Change
0.92 (1.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
88.75
Day's Low
85.72
Volume
(Light)
Volume:
97,735

10-day average volume:
133,269
97,735

Company Profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
5.42x
Price/Book (MRQ)
1.62x
Price/Cash Flow (TTM)
29.04x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

September 2022
Current Month
833.0K
Previous Month
808.2K
Percent of Float
5.22%
Days to Cover
6.8079 Days

Share Information

LGND is in a share class of common stock
Float
16.0M
Shares Outstanding
16.9M
Institutions Holding Shares
289
90.00%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • John W. Kozarich
  • Matthew William FoehrPres.
  • John L. HigginsCEO
  • Matthew Edward KorenbergCFO
  • Charles Stuart BerkmanSr.VP

Address

  • 3911 Sorrento Valley Blvd, Suite 110
  • San Diego, CA 92121
  • Phone: (858) 550-7500
  • Fax: (302) 636-5454
  • https://www.ligand.com/

Insider Trading

During the most recent quarter, 3K shares were bought, and 3K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.